BIOMAT Database Logo BIOMAT Database Logo

Design, synthesis and preliminary biological evaluation of 4-aminopyrazole derivatives as novel and potent JAKs inhibitors. 2016

Xuewu Liang, and Yongxue Huang, and Jie Zang, and Qianwen Gao, and Binghe Wang, and Wenfang Xu, and Yingjie Zhang
Department of Medicinal Chemistry, School of Pharmacy, Shandong University, Ji'nan, Shandong 250012, PR China.

JAKs inhibitors were widely applied in the treatment of immunodeficiency diseases, inflammation and cancers. We designed and synthesized a novel series of 4-aminopyrazole derivatives, which showed inhibitory potency against various JAKs. The in vitro protein kinase inhibition experiment indicated that compounds 17k, 17l, 17m and 17n could inhibit JAKs effectively. Among them, compound 17m possessed the highest protein kinase inhibitory rates (%) at 10μM, which were 97, 96 and 100 to JAK1, JAK2 and JAK3, respectively. Further evaluation revealed that the IC50 values of 17m against JAK1, JAK2 and JAK3 were 0.67μM, 0.098μM and 0.039μM, respectively. Moreover, western blotting results showed compound 17m could inhibit the phosphorylation of JAK2 in Hela cells effectively. The data supports the further investigation of these compounds as novel JAKs inhibitors.

UI MeSH Term Description Entries
D010766 Phosphorylation The introduction of a phosphoryl group into a compound through the formation of an ester bond between the compound and a phosphorus moiety. Phosphorylations
D011720 Pyrazoles Azoles of two nitrogens at the 1,2 positions, next to each other, in contrast with IMIDAZOLES in which they are at the 1,3 positions.
D011743 Pyrimidines A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.
D006367 HeLa Cells The first continuously cultured human malignant CELL LINE, derived from the cervical carcinoma of Henrietta Lacks. These cells are used for, among other things, VIRUS CULTIVATION and PRECLINICAL DRUG EVALUATION assays. Cell, HeLa,Cells, HeLa,HeLa Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs
D047428 Protein Kinase Inhibitors Agents that inhibit PROTEIN KINASES. Protein Kinase Inhibitor,Inhibitor, Protein Kinase,Inhibitors, Protein Kinase,Kinase Inhibitor, Protein,Kinase Inhibitors, Protein
D053612 Janus Kinases A family of intracellular tyrosine kinases that participate in the signaling cascade of cytokines by associating with specific CYTOKINE RECEPTORS. They act upon STAT TRANSCRIPTION FACTORS in signaling pathway referred to as the JAK/STAT pathway. The name Janus kinase refers to the fact the proteins have two phosphate-transferring domains. Janus Kinase,JAK Kinases,Kinase, Janus,Kinases, JAK,Kinases, Janus
D053614 Janus Kinase 2 A Janus kinase subtype that is involved in signaling from GROWTH HORMONE RECEPTORS; PROLACTIN RECEPTORS; and a variety of CYTOKINE RECEPTORS such as ERYTHROPOIETIN RECEPTORS and INTERLEUKIN RECEPTORS. Dysregulation of Janus kinase 2 due to GENETIC TRANSLOCATIONS have been associated with a variety of MYELOPROLIFERATIVE DISORDERS. JAK-2 Protein Tyrosine Kinase,JAK2 Protein Tyrosine Kinase,JAK 2 Protein Tyrosine Kinase

Related Publications

Xuewu Liang, and Yongxue Huang, and Jie Zang, and Qianwen Gao, and Binghe Wang, and Wenfang Xu, and Yingjie Zhang
Design, synthesis, and biological evaluation of novel piperidine-4-carboxamide derivatives as potent CCR5 inhibitors.
January 2014, European journal of medicinal chemistry,
Xuewu Liang, and Yongxue Huang, and Jie Zang, and Qianwen Gao, and Binghe Wang, and Wenfang Xu, and Yingjie Zhang
Design, synthesis and biological evaluation of novel 1, 3, 4-oxadiazole derivatives as potent neuraminidase inhibitors.
March 2022, Bioorganic & medicinal chemistry,
Xuewu Liang, and Yongxue Huang, and Jie Zang, and Qianwen Gao, and Binghe Wang, and Wenfang Xu, and Yingjie Zhang
Design, synthesis and biological evaluation of novel zanamivir derivatives as potent neuraminidase inhibitors.
December 2018, Bioorganic & medicinal chemistry letters,
Xuewu Liang, and Yongxue Huang, and Jie Zang, and Qianwen Gao, and Binghe Wang, and Wenfang Xu, and Yingjie Zhang
Design, Synthesis, and Biological Evaluation of Novel Acylhydrazone Derivatives as Potent Neuraminidase Inhibitors.
September 2020, ACS medicinal chemistry letters,
Xuewu Liang, and Yongxue Huang, and Jie Zang, and Qianwen Gao, and Binghe Wang, and Wenfang Xu, and Yingjie Zhang
Design, synthesis and biological evaluation of novel benzofuran derivatives as potent LSD1 inhibitors.
August 2021, European journal of medicinal chemistry,
Xuewu Liang, and Yongxue Huang, and Jie Zang, and Qianwen Gao, and Binghe Wang, and Wenfang Xu, and Yingjie Zhang
Design, synthesis and biological evaluation of novel pyrazolopyrimidone derivatives as potent PDE1 inhibitors.
September 2021, Bioorganic chemistry,
Xuewu Liang, and Yongxue Huang, and Jie Zang, and Qianwen Gao, and Binghe Wang, and Wenfang Xu, and Yingjie Zhang
Design, synthesis and biological evaluation of novel thiazole derivatives as potent FabH inhibitors.
December 2009, Bioorganic & medicinal chemistry letters,
Xuewu Liang, and Yongxue Huang, and Jie Zang, and Qianwen Gao, and Binghe Wang, and Wenfang Xu, and Yingjie Zhang
Design, synthesis and biological evaluation of novel oseltamivir derivatives as potent neuraminidase inhibitors.
December 2017, Bioorganic & medicinal chemistry letters,
Xuewu Liang, and Yongxue Huang, and Jie Zang, and Qianwen Gao, and Binghe Wang, and Wenfang Xu, and Yingjie Zhang
Design, Synthesis, and Antitumor Evaluation of 4-Amino-(1H)-pyrazole Derivatives as JAKs Inhibitors.
October 2016, ACS medicinal chemistry letters,
Xuewu Liang, and Yongxue Huang, and Jie Zang, and Qianwen Gao, and Binghe Wang, and Wenfang Xu, and Yingjie Zhang
Design, synthesis and biological evaluation of novel isoindolinone derivatives as potent histone deacetylase inhibitors.
April 2019, European journal of medicinal chemistry,
Copied contents to your clipboard!